Tech Company Financing Transactions

Carmot Therapeutics Funding Round

Carmot Therapeutics closed a $160 million Series D funding round on 7/26/2022. Investors included The Column Group, Deep Track Capital and Horizons Ventures.

Transaction Overview

Company Name
Carmot Therapeutics
Announced On
7/26/2022
Transaction Type
Venture Equity
Amount
$160,000,000
Round
Series D
Investors

The Column Group (Lead Investor) (Adriana Tajonar)

Deep Track Capital

Horizons Ventures (Patrick Zhang)

RA Capital

Willett Advisors

Proceeds Purpose
The company intends to use the funds for the completion of phase 2 studies for CT-388, a once weekly, dual modulator of the GLP-1 and GIP incretin receptors, phase 1 studies for CT-996, an oral small molecule GLP-1 receptor agonist, and phase 2 studies for CT-868, a first-in-class fully biased GLP-1/GIP modulator in addition to the advancement of several pre-clinical programs.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
USA
Phone
(888) 402-4674
Website
www.carmot-therapeutics.us
Email Address
[email protected]
Overview
Carmot Therapeutics develops drugs to treat inflammatory, metabolic and neurological diseases.
Profile
Carmot Therapeutics LinkedIn Company Profile
Social Media
Carmot Therapeutics Company Twitter Account
Company News
Carmot Therapeutics News
Facebook
Carmot Therapeutics on Facebook
YouTube
Carmot Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Stig Hansen
  Stig Hansen LinkedIn Profile  Stig Hansen Twitter Account  Stig Hansen News  Stig Hansen on Facebook
Chief Medical Officer
Allan Gordon
  Allan Gordon LinkedIn Profile  Allan Gordon Twitter Account  Allan Gordon News  Allan Gordon on Facebook
VP - Bus. Development
James Watson
  James Watson LinkedIn Profile  James Watson Twitter Account  James Watson News  James Watson on Facebook

 

 

Browse more venture capital transactions:

Prev: 7/26/2022: Butlr venture capital transaction
Next: 7/26/2022: Underdog venture capital transaction

 

Share this article

 

About Our VC Transactions Data

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.